AMSTERDAM, July 23, 2014 /PRNewswire/ --
QUOSA now offers customers with CCC
licenses the full benefits of integration at no extra cost,
significantly lowering barriers to copyright
compliance
Elsevier, a world-leading provider of scientific, technical and
medical information products and services, today announced that
QUOSA, its literature management solution, and Copyright Clearance
Center (CCC) have extended their relationship to support greater
compliance in the use of full text articles within corporate or
institutional environments. Using CCC's rights advisory API, QUOSA
customers who are also CCC licensees can view their license rights
directly from QUOSA at no extra cost to the user.
QUOSA users can instantly check the usage rights of documents
within the QUOSA library by accessing the CCC database via a single
user interface, helping them to quickly determine how they may use
a document; for example, checking if they can share an article with
colleagues. This significantly increases the efficiency of content
management workflows, helping users manage large libraries of
information and ensure compliance requirements are met. QUOSA and
CCC first partnered in 2009; the expansion of this relationship
will now deliver the same seamless functionality at no extra
cost.
"Ensuring compliance is a mammoth task for both researchers and
Information Managers alike. Users need to be sure they are using
documents in a compliant manner and Information Managers must avoid
the significant financial penalties that can result from failed
compliance," said Daan de Jong,
Director Product Development for Elsevier. "This latest enhancement
to QUOSA supports our drive to make QUOSA the 'one stop shop' for
literature management. Integrating QUOSA with per-article rights
data at no extra cost takes away the uncertainty surrounding
compliance that is experienced by pharmacovigilance and medical
affairs personnel when accessing scientific literature."
QUOSA is a centralized repository of scientific literature that
enables life sciences institutions to meet regulatory reporting
requirements, address medical inquiries and maintain current
awareness in relation to topics or authors. It is used by a broad
array of groups such as pharmacovigilance and medical affairs
personnel in pharma, biotech and medical device companies. CCC is a
leading global rights-licensing technology organization, providing
solutions that simplify compliance for content users, promoting the
work of creators and supporting the principles of copyright.
QUOSA is part of Elsevier's Life Science Solutions, a portfolio
of domain-specific, decision support tools which span the discovery
and development workflow and work together to support key research
outcomes. The portfolio includes Embase, Pathway Studio,
PharmaPendium, ScienceDirect, Scopus, TargetInsights, Reaxys and
Reaxys Medicinal Chemistry.
For more information on QUOSA please visit:
http://www.elsevier.com/online-tools/quosa
About Copyright Clearance Center
Copyright Clearance Center (CCC), a leading global
rights-licensing technology organization, provides solutions that
simplify compliance for content users, promotes the work of
creators and supports the principles of copyright. A rights broker
for the world's most sought-after journals, books, blogs, movies
and more, CCC makes it easy for businesses and academic
institutions to use, share and store copyrighted material while
compensating content creators for their works. With its
international subsidiary, RightsDirect, CCC serves more than 35,000
customers and 12,000 publishers around the world.
About Elsevier
Elsevier is a world-leading provider of information solutions
that enhance the performance of science, health, and technology
professionals, empowering them to make better decisions, deliver
better care, and sometimes make groundbreaking discoveries that
advance the boundaries of knowledge and human progress. Elsevier
provides web-based, digital solutions - among them
ScienceDirect, Scopus, Elsevier Research Intelligence and
ClinicalKey - and publishes nearly 2,200 journals, including The
Lancet and Cell, and over 25,000 book titles, including
a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading
provider of professional information solutions in the Science,
Medical, Legal and Risk and Business sectors, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols
are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and
ENL (New York Stock Exchange).
Media contact
Amy Burnis
Director, Strategic Communications
Elsevier
+1-617-803-8344
a.burnis@elsevier.com
SOURCE Elsevier
